Develops targeted protein-degrading drug candidates for patients with cancer and inflammatory diseases, and drug-discovery programs for biopharmaceutical partners.
10-K for FY2025, filed Jan 28, 2026
Biopharmaceutical companies work directly with Nurix through drug-discovery collaborations and licenses; Roche has an exclusive worldwide license to develop and commercialize bexobrutideg.
10-K for FY2025, filed Jan 28, 2026 8-K, filed Jun 8, 2026We have entered into several revenue generating collaborations with large biopharmaceutical companies, including Gilead, Sanofi and Pfizer…View ↗
No. It lost $264.5M in FY2025.
10-Q for Q3 FY2026, filed Oct 13, 2026
$549.8MView ↗
10-Q for Q3 FY2026, filed Oct 13, 2026
Open tableView ↗
8-K, filed Jun 8, 2026
Under the Collaboration Agreement, Roche will make an upfront cash payment of $700.0 million to Nurix, and Nurix will be eligible to…View ↗
A degrader-centered portfolio
The older report described both protein lowering and protein elevation and included a cell-therapy program; the latest centers on targeted protein degraders and includes degrader-antibody conjugates in preclinical work.
10-K for FY2022, filed Feb 9, 2023 10-K for FY2025, filed Jan 28, 2026We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein…View ↗
Our wholly owned pipeline of drug candidates comprises three clinical stage oncology programs and multiple preclinical stage Targeted…View ↗
In addition to our clinical stage drug candidates, we are advancing multiple preclinical-stage programs within our protein degradation…View ↗
An AI-integrated discovery platform
The older report described a discovery platform built around ligase expertise and compound libraries; the latest describes DEL-AI as AI-integrated, with machine learning and automated chemistry.
10-K for FY2022, filed Feb 9, 2023 10-K for FY2025, filed Jan 28, 2026We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule and cell…View ↗
An expanded collaboration roster
The older report described collaborations with Gilead and Sanofi; the latest also names Pfizer as a drug-discovery partner.
10-K for FY2022, filed Feb 9, 2023 10-K for FY2025, filed Jan 28, 2026We have entered into several revenue generating collaborations with large biopharmaceutical companies to leverage our DELigase platform for…View ↗
We have entered into several revenue generating collaborations with large biopharmaceutical companies, including Gilead, Sanofi and Pfizer…View ↗
Loading...